Search Results - "Aldinucci, Donatella"

Refine Results
  1. 1

    The Inflammatory Chemokine CCL5 and Cancer Progression by Aldinucci, Donatella, Colombatti, Alfonso

    Published in Mediators of Inflammation (01-01-2014)
    “…Until recently, inflammatory chemokines were viewed mainly as indispensable “gate keepers” of immunity and inflammation. However, updated research indicates…”
    Get full text
    Journal Article
  2. 2

    Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer by Aldinucci, Donatella, Casagrande, Naike

    “…Despite the progress made in molecular and clinical research, patients with advanced-stage gastric cancer (GC) have a bad prognosis and very low survival…”
    Get full text
    Journal Article
  3. 3

    The CCL5/CCR5 Axis in Cancer Progression by Aldinucci, Donatella, Borghese, Cinzia, Casagrande, Naike

    Published in Cancers (02-07-2020)
    “…Tumor cells can “hijack” chemokine networks to support tumor progression. In this context, the C-C chemokine ligand 5/C-C chemokine receptor type 5 (CCL5/CCR5)…”
    Get full text
    Journal Article
  4. 4

    Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It by Aldinucci, Donatella, Borghese, Cinzia, Casagrande, Naike

    “…Classic Hodgkin lymphoma (cHL) is characterized by a few tumor cells surrounded by a protective, immunosuppressive tumor microenvironment composed of normal…”
    Get full text
    Journal Article
  5. 5

    CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth by Casagrande, Naike, Borghese, Cinzia, Visser, Lydia, Mongiat, Maurizio, Colombatti, Alfonso, Aldinucci, Donatella

    Published in Haematologica (Roma) (01-03-2019)
    “…Classic Hodgkin lymphoma tumor cells express a functional CCR5 receptor, and tumor tissues express high CCL5 levels, suggesting that CCL5-CCR5 signaling is…”
    Get full text
    Journal Article
  6. 6

    In ovarian cancer maraviroc potentiates the antitumoral activity and further inhibits the formation of a tumor-promoting microenvironment by trabectedin by Casagrande, Naike, Borghese, Cinzia, Corona, Giuseppe, Aldinucci, Donatella

    Published in Biomedicine & pharmacotherapy (01-03-2024)
    “…Ovarian cancer (OC) is the fifth most frequent cause of cancer-related death in women. Chemotherapy agent trabectedin, affecting cancer cells and tumor…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9

    Analogs of a Natural Peptaibol Exert Anticancer Activity in Both Cisplatin- and Doxorubicin-Resistant Cells and in Multicellular Tumor Spheroids by Casagrande, Naike, Borghese, Cinzia, Gabbatore, Laura, Morbiato, Laura, De Zotti, Marta, Aldinucci, Donatella

    “…Peptaibols, by disturbing the permeability of phospholipid membranes, can overcome anticancer drug resistance, but their natural hydrophobicity hampers their…”
    Get full text
    Journal Article
  10. 10

    Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance by Borghese, Cinzia, Casagrande, Naike, Corona, Giuseppe, Aldinucci, Donatella

    Published in Pharmaceutics (27-04-2020)
    “…Adipose-derived stem cells (ADSCs) primed with paclitaxel (PTX) are now hypothesized to represent a potential Trojan horse to vehicle and deliver PTX into…”
    Get full text
    Journal Article
  11. 11

    The role of the EGFR signaling in tumor microenvironment by De Luca, Antonella, Carotenuto, Adele, Rachiglio, Annamaria, Gallo, Marianna, Maiello, Monica R., Aldinucci, Donatella, Pinto, Antonio, Normanno, Nicola

    Published in Journal of cellular physiology (01-03-2008)
    “…The epidermal growth factor receptor (EGFR) family comprehends four different tyrosine kinases (EGFR, ErbB‐2, ErbB‐3, and ErbB‐4) that are activated following…”
    Get full text
    Journal Article
  12. 12

    In Doxorubicin-Adapted Hodgkin Lymphoma Cells, Acquiring Multidrug Resistance and Improved Immunosuppressive Abilities, Doxorubicin Activity Was Enhanced by Chloroquine and GW4869 by Casagrande, Naike, Borghese, Cinzia, Avanzo, Michele, Aldinucci, Donatella

    Published in Cells (Basel, Switzerland) (29-11-2023)
    “…Classical Hodgkin lymphoma (cHL) is a highly curable disease (70-80%), even though long-term toxicities, drug resistance, and predicting clinical responses to…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Expression of CCR5 receptors on Reed–Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions by Aldinucci, Donatella, Lorenzon, Debora, Cattaruzza, Lara, Pinto, Antonio, Gloghini, Annunziata, Carbone, Antonino, Colombatti, Alfonso

    Published in International journal of cancer (15-02-2008)
    “…The expression of CCL5/Rantes by Hodgkin (H) and Reed‐Sternberg (RS) cells has been recently documented. In the present study we demonstrated that the CCL5…”
    Get full text
    Journal Article
  15. 15

    Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells by De Luca, Antonella, Gallo, Marianna, Aldinucci, Donatella, Ribatti, Domenico, Lamura, Luana, D'Alessio, Amelia, De Filippi, Rosaria, Pinto, Antonio, Normanno, Nicola

    Published in Journal of cellular physiology (01-08-2011)
    “…Increasing evidence suggests that bone marrow‐derived mesenchymal stem cells (MSCs) are recruited into the stroma of developing tumors where they contribute to…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes by Ronconi, Luca, Aldinucci, Donatella, Dou, Q Ping, Fregona, Dolores

    Published in Anti-cancer agents in medicinal chemistry (01-05-2010)
    “…In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the…”
    Get more information
    Journal Article
  18. 18
  19. 19
  20. 20

    Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts by Celegato, Marta, Borghese, Cinzia, Casagrande, Naike, Carbone, Antonino, Colombatti, Alfonso, Aldinucci, Donatella

    Published in Leukemia & lymphoma (01-01-2014)
    “…Abstract Bortezomib is a proteasome inhibitor active in classical Hodgkin lymphoma (cHL) cell lines, but poorly active in the clinic when used as a single…”
    Get full text
    Journal Article